Clinical Trial Update: Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating everolimus as second-line therapy in metastatic renal cell carcinoma has been completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-02